Skip to content

Trial Summary

This is a phase II/III, global, multicenter, open-label, multi-cohort study designed to evaluatethe safety and efficacy of targeted therapies or immunotherapy as single agents or incombination in participants with unresectable, advanced or metastatic NS

Acronym:

BO29554 B.FAST

ACTRN/NCT /ethics:

NCT03178552

Scientific title:

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Sponsor / Cooperative group:

Roche

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase II, Phase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2017-09-22
Anticipated End Date-

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruiting